Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Reduces Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 133,775 shares of the company's stock after selling 684 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned approximately 0.17% of IDEXX Laboratories worth $57,072,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories in the fourth quarter worth $30,000. Colonial Trust Co SC raised its holdings in IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares in the last quarter. Itau Unibanco Holding S.A. lifted its position in IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after buying an additional 81 shares during the period. Finally, Retirement Wealth Solutions LLC boosted its holdings in shares of IDEXX Laboratories by 40.0% during the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock valued at $44,000 after buying an additional 30 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Stifel Nicolaus increased their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Finally, Leerink Partners boosted their price target on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $546.00.

IDEXX Laboratories Stock Down 0.5%

Shares of IDEXX Laboratories stock opened at $527.78 on Friday. The company has a 50-day simple moving average of $496.62 and a two-hundred day simple moving average of $450.16. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $533.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The stock has a market capitalization of $42.44 billion, a PE ratio of 48.78, a price-to-earnings-growth ratio of 3.87 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The company had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same period in the previous year, the business earned $2.71 EPS. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now owns 1,801 shares in the company, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.